title: The role of androgens in female sexual dysfunction.
abstract: There are many treatment options for female sexual dysfunction (FSD), with the optimal therapy depending on the etiology of the problem. The cause of sexual dysfunction is multifactorial and may include psychological problems such as depression or anxiety disorders, conflict within the relationship, partner performance and technique, issues relating to prior abuse, medical illness, medications, fatigue, stress, or gynecological problems that make sexual activity uncomfortable. The role of low androgen concentrations in FSD is gaining increasing attention. Available therapeutic options include adjusting medications, counseling, treating depression or anxiety, reducing stress and fatigue, sex therapy, devices, estrogen therapy for genitourinary atrophy, and possibly vasoactive substances. Although no androgen therapies are currently approved by the Food and Drug Administration for FSD, they are being used in clinical practice, and early clinical trial results suggest that they may be both effective and safe in the treatment of FSD, specifically low libido. Androgen therapy should be considered primarily in women who have a physiological reason for reduced androgen concentrations, including aging, hypopituitarism, oophorectomy, or adrenal insufficiency. Products in use include oral methyltestosterone and dehydroepiandrosterone, topical testosterone ointment, and testosterone implants and injections. Products available for men, including skin patches and gels, are currently being studied at doses appropriate for women. Possible risks include hirsutism, acne, liver dysfunction, lowering of the voice, adverse lipid changes, virilization of a female fetus, and, as androgens are aromatized to estrogens, potentially the risks of estrogen therapy.
authors.affiliation: Menopause Program, Vincent Memorial Obstetrics and Gynecology Service, Massachusetts General Hospital and Harvard Medical School, Boston, Mass 02114, USA.
authors.forename: Jan L
authors.initials: JL
authors.lastname: Shifren
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D000728:Androgens / Q000737:chemistry / Q000172:deficiency / Q000502:physiology / Q000627:therapeutic use; D001143:Arousal / Q000187:drug effects / Q000502:physiology; D002626:Chemistry, Pharmaceutical; D002986:Clinical Trials as Topic; D003687:Dehydroepiandrosterone / Q000737:chemistry / Q000627:therapeutic use; D004343:Drug Implants; D005260:Female; D005782:Gels; D020249:Hormone Replacement Therapy / Q000009:adverse effects / Q000379:methods; D006801:Humans; D007273:Injections, Intramuscular; D007989:Libido / Q000187:drug effects / Q000502:physiology; D008593:Menopause / Q000187:drug effects / Q000502:physiology / Q000523:psychology; D008777:Methyltestosterone / Q000737:chemistry / Q000627:therapeutic use; D018579:Patient Selection; D017697:Premenopause / Q000187:drug effects / Q000502:physiology / Q000523:psychology; D012720:Severity of Illness Index; D012731:Sex Counseling; D020018:Sexual Dysfunctions, Psychological / Q000209:etiology / Q000523:psychology / Q000628:therapy; D013739:Testosterone / Q000737:chemistry / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000728:Androgens; D004343:Drug Implants; D005782:Gels; D013739:Testosterone; D003687:Dehydroepiandrosterone; D008777:Methyltestosterone